Sjoerd Rodenhuis
#167,393
Most Influential Person Now
Sjoerd Rodenhuis's AcademicInfluence.com Rankings
Sjoerd Rodenhuismedical Degrees
Medical
#3462
World Rank
#3931
Historical Rank
Oncology
#242
World Rank
#250
Historical Rank

Sjoerd Rodenhuisphilosophy Degrees
Philosophy
#9922
World Rank
#13552
Historical Rank
Logic
#6874
World Rank
#8431
Historical Rank

Download Badge
Medical Philosophy
Sjoerd Rodenhuis's Degrees
- Doctorate Medicine University of Amsterdam
Why Is Sjoerd Rodenhuis Influential?
(Suggest an Edit or Addition)Sjoerd Rodenhuis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
- A gene-expression signature as a predictor of survival in breast cancer. (2002) (3325)
- Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. (1998) (766)
- Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. (1987) (547)
- Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. (1988) (494)
- Clinical significance of ras oncogene activation in human lung cancer. (1992) (417)
- Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. (2005) (413)
- Clinical Pharmacokinetics of Cyclophosphamide (1979) (373)
- Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome (2003) (302)
- Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). (2007) (277)
- The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer (2010) (265)
- Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. (2011) (264)
- High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. (2003) (261)
- Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. (2002) (258)
- Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement (1998) (245)
- ras and human tumors. (1992) (243)
- Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. (2007) (240)
- Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. (1991) (236)
- Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of (2000) (226)
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcom (2010) (194)
- Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. (1995) (191)
- Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers (2013) (190)
- Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. (2005) (189)
- Malignant effusions contain lysophosphatidic acid (LPA)-like activity. (1998) (188)
- An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients (2010) (182)
- C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. (1994) (181)
- Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response (2009) (175)
- K‐ras oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung (1993) (153)
- Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantation. (1995) (145)
- The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy (2010) (139)
- In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. (2001) (129)
- Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide (2008) (125)
- The ras oncogenes in human lung cancer. (1990) (123)
- 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques (2011) (121)
- High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. (1990) (107)
- Detection of circulating breast tumor cells by differential expression of marker genes. (2002) (106)
- Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver (1991) (105)
- Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. (2005) (103)
- Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. (2008) (100)
- Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients (2003) (100)
- Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation (2005) (100)
- High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. (2011) (99)
- Overexpression of the p53 Tumor Suppressor Gene Product in Primary Lung Adenocarcinomas Is Associated with Cigarette Smoking (1993) (98)
- Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. (1996) (96)
- Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy (2012) (96)
- Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. (1997) (95)
- Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy (2014) (93)
- An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. (2009) (90)
- Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer (2012) (90)
- Patient motivation and informed consent in a phase I study of an anticancer agent. (1984) (89)
- Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. (1990) (88)
- Comparative analysis of p53 gene mutations and protein accumulation in human non‐small‐cell lung cancer (1995) (87)
- K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. (1993) (85)
- Accuracy, feasibility and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high‐dose chemotherapy (2005) (82)
- Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response (2013) (81)
- FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. (2013) (80)
- Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. (2011) (80)
- Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia. (1985) (80)
- Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. (1993) (78)
- Neoadjuvant chemotherapy in ER+ HER2− breast cancer: response prediction based on immunohistochemical and molecular characteristics (2012) (77)
- Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. (1997) (77)
- Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness (2011) (76)
- Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. (1994) (75)
- High-dose chemotherapy regimens for solid tumors. (1995) (75)
- Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. (1986) (72)
- The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. (1998) (71)
- Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. (2006) (71)
- Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction, and nucleic acid sequence–based amplification for the detection of circulating breast cancer cells (1999) (70)
- Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion (2000) (69)
- Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion. (1995) (68)
- Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy (2006) (68)
- Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. (1999) (66)
- High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy (2006) (66)
- A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. (1999) (64)
- Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody (2005) (64)
- Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy (2012) (62)
- Management of intermediate‐prognosis germ‐cell cancer: Results of a phase I/II study of Taxol‐BEP (1999) (62)
- Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism (2005) (61)
- Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy (2013) (60)
- Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. (2009) (59)
- Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response (2015) (58)
- Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. (2002) (58)
- Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. (2002) (58)
- Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. (2004) (55)
- Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods (2000) (55)
- The ras gene family in human non-small-cell lung cancer. (1992) (54)
- N‐ and KRAS mutations in primary testicular germ cell tumors: Incidence and possible biological implications (1995) (54)
- Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? (2009) (53)
- Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin (2008) (52)
- SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer (2012) (52)
- Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. (1991) (51)
- Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function (2006) (51)
- Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens (2000) (50)
- Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer. (1989) (49)
- Predicting Early Failure after Adjuvant Chemotherapy in High-Risk Breast Cancer Patients with Extensive Lymph Node Involvement (2004) (49)
- A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. (2010) (47)
- The clinical pharmacology of alkylating agents in high-dose chemotherapy. (2000) (47)
- Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). (2007) (46)
- Resistance to cisplatin and analogues: mechanisms and potential clinical implications. (1988) (46)
- Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla (2013) (45)
- Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support. (1996) (45)
- A Rapid and Simple Procedure for the Routine Detection of ras Point Mutations in Formalin‐Fixed, Paraffin‐Embedded Tissues (1992) (45)
- Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy (2002) (44)
- Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. (1992) (44)
- High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach. (1995) (44)
- Combined use of 18F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy (2014) (43)
- The molecular genetics of human lung cancer. (1989) (42)
- Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin (2002) (42)
- A Mechanism-Based Pharmacokinetic Model for the Cytochrome P450 Drug–Drug Interaction between Cyclophosphamide and ThioTEPA and the Autoinduction of Cyclophosphamide (2001) (42)
- A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. (1992) (41)
- At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. (1999) (40)
- Growth factors in human ovarian cancer. (1997) (39)
- Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin (1995) (39)
- Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure (1996) (39)
- Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. (2009) (38)
- Prognostic factors in NSCLC. Recent experiences. (1995) (38)
- Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood (1986) (38)
- The use of the Calvert formula to determine the optimal carboplatin dosage (2005) (37)
- Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin (2005) (37)
- Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer (2003) (35)
- Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. (2012) (33)
- Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator. (1993) (32)
- Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. (2007) (31)
- Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site (2020) (30)
- Population Pharmacokinetics of Cyclophosphamide and Its Metabolites 4-Hydroxycyclophosphamide, 2-Dechloroethylcyclophosphamide, and Phosphoramide Mustard in a High-Dose Combination With Thiotepa and Carboplatin (2005) (28)
- HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC DETERMINATION OF THE STABILIZED CYCLOPHOSPHAMIDE METABOLITE 4-HYDROXYCYCLOPHOSPHAMIDE IN PLASMA AND RED BLOOD CELLS (2000) (28)
- Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography. (2000) (27)
- Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. (1998) (27)
- Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients (2008) (26)
- The status of high-dose chemotherapy in breast cancer. (2000) (26)
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (26)
- Integrated Population Pharmacokinetic Model of Both Cyclophosphamide and Thiotepa Suggesting a Mutual Drug–Drug Interaction (2004) (26)
- Resistance ot cisplatin and analogues: mechanisms and potential clinical implications (2004) (25)
- Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. (2001) (25)
- A search for new metabolites of N,N',N''-triethylenethiophosphoramide. (1999) (25)
- Absence of ras gene mutations in early gastric carcinomas. (1995) (24)
- Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study (2004) (24)
- Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer (2013) (24)
- Increase of dihydrofolate reductase in peripheral blood lymphocytes of rheumatoid arthritis patients treated with low-dose oral methotrexate. (1987) (23)
- Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. (1986) (23)
- Invasive pulmonary aspergillosis in a non-immunosuppressed patient: successful management with systemic amphotericin and flucytosine and inhaled amphotericin. (1984) (23)
- Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience (2003) (22)
- Breast cancer studies in the Netherlands (1996) (22)
- Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. (2005) (21)
- The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis. (1996) (21)
- Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheter. (1994) (21)
- Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. (1999) (21)
- Identifying subgroup markers in heterogeneous populations (2013) (20)
- Serum beta2‐microglobulin: a real improvement in the management of multiple myeloma? (1985) (20)
- Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study. (2017) (19)
- Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer. (2002) (19)
- Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer (2016) (19)
- Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II–III breast cancer patients treated with neoadjuvant chemotherapy (2013) (19)
- Monitoring tumor response to neoadjuvant chemotherapy using MRI and 18F-FDG PET/CT in breast cancer subtypes (2017) (18)
- Monitoring Carboplatin Concentrations in Saliva: A Replacement for Plasma Ultrafiltrate Measurements? (1995) (18)
- Feasibility study of FEC-chemotherapy with dose-intensive epirubicin as initial treatment in high-risk breast cancer. (1993) (18)
- Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. (1995) (18)
- Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma. A multicentre phase II study. (1989) (17)
- Intraperitoneal chemotherapy for malignant peritoneal mesothelioma. (1991) (17)
- Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. (1997) (17)
- Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. (1997) (17)
- Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients. (1996) (16)
- Sampling technique from central venous catheters proves critical for pharmacokinetic studies. (1999) (16)
- Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support (1995) (15)
- A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen (1999) (15)
- Oncogenes and human lung cancer. (1989) (15)
- Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer (2001) (15)
- [Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]. (2008) (14)
- Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency (2008) (14)
- Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. (2013) (14)
- Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma (2001) (13)
- Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute. (1992) (13)
- Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes (2005) (13)
- Paclitaxel, Carboplatin, and Trastuzumab in a Neo‐adjuvant Regimen for HER2‐positive Breast Cancer (2013) (13)
- Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours. (1996) (13)
- A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. (1993) (13)
- Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin (2001) (12)
- Association of H‐ras mutations with adenocarcinomas of the parotid gland (1994) (12)
- Inefficacy of Plasma Exchange in Cold Agglutinin Hemolytic Anemia — A Case Study (1985) (11)
- Successful intraperitoneal suramin treatment of peritoneal mesothelioma. (1997) (11)
- EAP in advanced gastric cancer. (1990) (11)
- Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer. (1992) (11)
- Carbamazepine induces bioactivation of cyclophosphamide and thiotepa (2009) (11)
- Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells. (1987) (11)
- A Method to Monitor mRNA Levels in Human Breast Tumor Cells Obtained by Fine‐needle Aspiration (1997) (11)
- Alternating recombinant human interleukin-2 and dacarbazine in advanced melanoma. A multicentric phase II study. (1989) (11)
- Allele‐specific detection of K‐ras oncogene expression in human non‐small‐cell lung carcinomas (2007) (10)
- Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma. (2001) (10)
- Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study. (1999) (10)
- Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination (2004) (10)
- Invasive aspergillosis complicated by subclavian artery occlusion and costal osteomyelitis after autologous bone marrow transplantation. (1992) (9)
- Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography. (1998) (9)
- 0073 The 70-gene MammaPrint signature is predictive for chemotherapy benefit in early breast cancer (2009) (9)
- High-dose chemotherapy in breast cancer - interpretation of the randomized trials (2001) (9)
- Validation of a Therapeutic Drug Monitoring Strategy for Thiotepa in a High-Dose Chemotherapy Regimen (2001) (9)
- Breast Cancer Subtype Specific Classifiers of Response to Neoadjuvant Chemotherapy Do Not Outperform Classifiers Trained on All Subtypes (2014) (9)
- Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization. (2009) (9)
- Neutropenic enterocolitis in a patient with ovarian cancer after treatment with high-dose carboplatin and granulocyte macrophage-colony stimulating factor (GM-CSF). (1990) (9)
- Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy (2000) (9)
- Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients (2008) (8)
- Sorption of Thiotepa to Polyurethane Catheter Causes Falsely Elevated Plasma Levels (2003) (8)
- Peripheral Blood Stem Cell (PBSC) Mobilization and Transplantation (PSCT) in Patients with Malignant Lymphomas and Solid Tumors (1993) (8)
- Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone (2004) (8)
- A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive epithelial ovarian cancer (eoc) (2010) (8)
- Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy. (2012) (7)
- Is high-dose chemotherapy dead? (2005) (7)
- Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel (2007) (7)
- Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer (2017) (7)
- The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure (2015) (6)
- Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer (2004) (6)
- Sparse Sampling Design for Therapeutic Drug Monitoring of Sequentially Administered Cyclophosphamide, Thiotepa, and Carboplatin (CTC) (2005) (6)
- Prediction of response to neoadjuvant chemotherapy in breast cancer. (2006) (6)
- Effect of Cisplatin-Containing Chemotherapy on Lithium Serum Concentrations (1992) (6)
- Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer. (1992) (6)
- Early onset of oral aphthous ulcers with weekly docetaxel. (2005) (6)
- Clinical pharmacokinetics of (NPAz2)2NSOAz: ‘SOAz’ (2004) (5)
- High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer. (2000) (5)
- Successful docetaxel rechallenge with cromoglycate after major sensitivity reactions. (1996) (5)
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies (2008) (5)
- Recurrent breast cancer and an adenocarcinoma of the lung occurring in one patient: c-myc oncogene amplification and K-ras codon 12 point mutation as tumour markers. (1988) (4)
- Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer : Update of the Dutch randomized (2005) (4)
- Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy. (2003) (4)
- Downstaging of an Advanced Gastrointestinal Stromal Tumor by Neoadjuvant Imatinib (2004) (4)
- Pharmacokinetics of Cyclophosphamide and Thiotepa in a Conventional Fractionated High-Dose Regimen Compared With a Novel Simplified Unfractionated Regimen (2009) (4)
- Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient? (2015) (4)
- Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion (1996) (4)
- Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: a dose-finding study. (1993) (4)
- Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial (2005) (4)
- PP-5-1 Preliminary analysis of a randomized phase II study of high-dose chemotherapy in high-risk breast cancer (1996) (3)
- NEW DESIGNS AND STRUCTURE ACTIVITY RELATIONSHIPS IN ANTITUMORAL AZIRIDINYL CYCLOPHOSPHA(THIA)ZENES (1983) (3)
- Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology. (2009) (3)
- 940 Phase I and pharmacokinetic study of topotecan (T) in combination with oral etoposide (E) (1995) (3)
- Tauromustine (TCNU) combined with 5-fluorouracil and leucovorin in the treatment of advanced colon cancer. (1993) (3)
- Phase i clinical trial of (NPAz2)2NSOAz: ‘SOAz’ (2004) (3)
- Phase I evaluation of SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6, 2,4,6,3 lambda 5, 5 lambda 5 thiatriaza-diphosphorine-1-oxide) in a weekly schedule. (1984) (3)
- Oral Bioavailability of Low Dose (20mg) ‘Home-Made’ Etoposide Capsules (1996) (3)
- Reconstitution of interleukin-2 (1990) (3)
- 0074 Early prognosis prediction: MammaPrint on core-needle biopsies (2009) (2)
- Changes in gene expression profiling due to primary chemotherapy in patients with locally advanced breast cancer. (2004) (2)
- Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness, and as such treatment response. (2011) (2)
- PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease. (2017) (2)
- [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. (2006) (2)
- A randomized single-institution study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin (CTC) in apical node-positive breast cancer (1997) (2)
- Genomic patterns resembling BRCA-mutated breast cancers and benefit of intensified carboplatin-based chemotherapy in HER2-negative breast cancer. (2011) (2)
- P3-14-17: Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant Regimen for HER2−Positive Breast Cancer: The TRAIN Study. (2011) (2)
- Determination of the antitumor agent SOAz (1,3,3,5,5 Pentakis(Aciridino)-1λ6,2,4,6,3λ5,5λ5 Thia-Triazadiphosphorine-1-Oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in man (2004) (2)
- The Diagnosis of Tumors. (1946) (2)
- 7 Relevance of Breast Cancer Subtypes in Response Monitoring with 18F-FDG PET/CT During Neoadjuvant Chemotherapy (2012) (2)
- Interpretation of contrast enhanced MRI for early prediction of breast-cancer response to neoadjuvant chemotherapy: Initial results (2008) (2)
- Clinical pharmacokinetics of (NPAz 2 ) 2 NSOAz: SOAz (1983) (2)
- 12 Multiple courses of high-dose alkylating therapy with autologous stem cell support (1995) (1)
- Abstract P4-21-30: Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle (2017) (1)
- Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer (2005) (1)
- Dose-intensive chemotherapy for locally advanced breast cancer (1999) (1)
- High-dose chemotherapy in breast cancer. The Dutch trial (2001) (1)
- Third-party payers and breast cancer study. (1998) (1)
- Comprehensive characterization of matched pre-treatment biopsies and residual disease of chemotherapy treated breast cancer (2016) (1)
- Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxatrone (Short communication) (1992) (1)
- High-dose chemotherapy in solid tumors (1999) (1)
- An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy. (2013) (1)
- First experiences with the use of imatinib in gastrointestinal stromal tumours (2006) (1)
- High-dose chemotherapy for breast cancer - To the editor (1997) (1)
- [High-dose chemotherapy with stem cell support for solid tumors in adults]. (1999) (1)
- New treatment opportunities in non-small cell lung cancer (1993) (1)
- Gunstig effect van uit het bloed geïsoleerde hematopoëtische stamcellen op het hematologisch herstel na hooggedoseerde chemotherapie (1993) (1)
- Homologous recombination defects in sporadic breast cancers (2008) (1)
- High-Dose Chemotherapy for Breast Cancer (1997) (1)
- [Recurrent upper respiratory tract infections during and after rituximab therapy]. (2015) (1)
- High-dose chemotherapy for breast cancer - Reply (2003) (1)
- Joint Accreditation Committee of the International Society for Cellular Therapy and the European Group for Blood and Marrow Transplantation accreditation for autologous hematopoietic stem cell transplantation in non-leukemic malignancies: burden or benefit? (2016) (1)
- The pharmacokinetics of reduced folates after intraperltoneal and intravenous administration of racemic [6S,R]-folinic acid (2004) (1)
- 258 Evaluation of radioactive seed versus radio guided localization in breast conserving surgery after primary systemic therapy (2010) (1)
- Abstract P4-02-01: 18F-FDG PET/CT for the assessment of locoregional lymph node involvement and radiotherapy indication in stage II-III breast cancer treated with neoadjuvant chemotherapy (2012) (1)
- A High-Dose Carboplatin-Based Salvage Strategy for Relapsing or Refractory Germ Cell Cancer (1994) (1)
- ras oncogene activation and the expression of ras-related genes in human lung cancer (1993) (1)
- Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients. (1997) (1)
- Clinical relevance of the use of FDG PET/CT in locally advanced breast cancer. (2012) (1)
- Abstract PD07-07: Indicators of Homologous Recombination Deficiency in Breast Cancer and Association with Response to Neoadjuvant Chemotherapy (2010) (1)
- High-dose chemotherapy and stem-cell support in breast cancer (multiple letters) [1] (1998) (0)
- Randomized studies of high dose chemotherapy in high-risk breast cancer in The Netherlands (1999) (0)
- 970O CARBOPLATIN PLUS PACLITAXEL VERSUS CARBOPLATIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN AS FIRST- LINE TREATMENT FOR PATIENTS WITH OVARIAN CANCER: THE MITO-2 (MULTICENTRE ITALIAN TRIALS IN OVARIAN CANCER) RANDOMIZED PHASE III TRIAL (2010) (0)
- Detection of homologous recombination defects in biopsies of sporadic breast cancers (2008) (0)
- Abstract 1192: Triple negative breast cancer: BRCAness and concordance of clinical features and treatment response with BRCA1 mutation carriers. (2013) (0)
- The role of high-dose chemotherapy in breast cancer (2006) (0)
- Risk factors for early recurrences after conventional- or high-dose adjuvant chemotherapy in breast cancer patients with extensive lymph node involvement (2004) (0)
- Cognitive functions after chemotherapy (2004) (0)
- Fulvestrant in heavily pre-treated breast cancer patients-Single institution experience. (2006) (0)
- 139. Relevance of breast cancer subtypes in response monitoring with 18F-FDG PET/CT during neoadjuvant chemotherapy (2012) (0)
- 155. Locoregional lymph node involvement on 18F-FDG PET/CT and estimation of risk for locoregional recurrence in stage II–III breast cancer patients (2012) (0)
- Abstracts of papers Pharmaceutical and biomedical analysis meeting (2005) (0)
- Chemotherapie mammacarcinoom (2003) (0)
- Prospective analysis of mRNA expression signatures as predictive tests in primary breast cancer (2007) (0)
- GYNECOLOGIC ONCOLOGY ISSUES IN THE 8TH IGCS MEETING OF BUENOS AIRES (2000) (0)
- Reviewers of the Journal of Chemotherapy (2010) (0)
- Preventie en therapie van tumoren (2002) (0)
- Erratum: Predicting early failure in node-positive breast cancer (Clinical Cancer Research (July 1)) (2004) (0)
- Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response (2015) (0)
- High-dose chemotherapy in breast cancer: Dutch randomized studies (2001) (0)
- [A look over the horizon of cancer treatment. The internist]. (1989) (0)
- High-dose chemotherapy and stem-cell support in breast cancer (1998) (0)
- PP65. Economic evaluation of high dose chemotherapy for breast cancer patients (1997) (0)
- Abstract P3-06-21: Next generation sequencing to find predictors for chemotherapy response in triple negative breast cancer (2015) (0)
- High-dose chemotherapy and stem-cell support in breast cancer. Authors' reply (1998) (0)
- Genotyping as tool for dose individualisation in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin (2005) (0)
- [Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy]. (1993) (0)
- Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site (2023) (0)
- Abstract 4820: A clinical test for BRCAness: Using array comparative genomic hybridization to predict benefit of high-dose, platinum-containing chemotherapy in ER-low/HER2-negative breast cancer patients (2010) (0)
- OC-0130 18F-FDG PET/CT FOR THE ASSESSMENT OF LOCOREGIONAL LYMPH NODE INVOLVEMENT IN STAGE II AND III BREAST CANCER (2012) (0)
- Invasive pulmonary aspergillosis inanon-immunosuppressed patient: successful managementwithsystemic amphotericin andflucytosine andinhaled amphotericin (1984) (0)
- Abstract PD1-07: Comprehensive characterization of matched pre-treatment biopsies and residual disease of doxorubicin treated breast cancer (2017) (0)
- Abstract 3134: Neoadjuvant chemotherapy in ER+HER2- breast cancer: Response prediction based on immunohistochemical and molecular characteristics (2011) (0)
- REVIEW OF CARBOPLATIN-BASED HIGH-DOSE CHEMOTHERAPY COMBINATIONS IN THE AUTOTRANSPLANT SETTING (1996) (0)
- Managing patients at home during the aplastic phase of high dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT) (1999) (0)
- High-dose chemotherapy in breast cancer : In favor! (2000) (0)
- 1st National Congress of the Hellenic Society of Digestive Surgery (2004) (0)
- Detection of minimal disease in breast cancer (2005) (0)
- Individualized chemotherapy doses with granulocyte colony stimulating factor support have survival and toxicity benefits over marrow supported high dose chemotherapy (2001) (0)
- HIGH-DOSE CHEMOTHERAPY FOR BREAST CANCER. AUTHOR'S REPLY (1997) (0)
- PD03-08: BRCA1-Like Triple Negative Tumors: Clinicopathological Variables and Chemosensitivity to Alkylating Agents. (2011) (0)
- Benefit of the 70-gene profile for widely used guidelines: an answer to increased selection for adjuvant chemotherapy in breast cancer. (2009) (0)
- Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer (2016) (0)
- Prevention and therapy of tumors (2002) (0)
- Early Clinical Studies of (NPAz2)2NSOAz (1983) (0)
- Next-generation sequencing to find predictors for chemotherapy response in triple-negative breast cancer (TNBC). (2013) (0)
- Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy. (2012) (0)
- Efficacy of high-dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer (2005) (0)
- Abstract 22: Identifying chemotherapy resistance genes using outlier detection (2011) (0)
- Abstract PD06-06: Novel Surgical Technique To Assess the Response of Metastatic Axillary Lymph Nodes to Neoadjuvant Chemotherapy in Breast Cancer Patients (2010) (0)
- Determination of the antitumor agent SOAz (1,3,3,5,5 pentakis(aziridino)-1 lambda 6,2,4,6,3 lambda 5, 5 lambda 5 thia-triazadiphosphorine-1-oxide) by a gas chromatographic assay suitable for pharmacokinetic studies in man. (1983) (0)
- Abstract OT1-1-01: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - The TRAIN-2 study (2013) (0)
- Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy (2014) (0)
- [Centralising cancer treatment: a good idea]. (2011) (0)
- High dose chemotherapy in breast cancer reviewed (1995) (0)
- EZH2 is overexpressed in breast tumors with a BRCA1-like DNA copy number profile (2015) (0)
- Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study (2016) (0)
- P72. Prediction of response to preoperative chemotherapy in locally advanced breast cancer (2006) (0)
- P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial. (2011) (0)
- Drug resistance. (1989) (0)
- High-dose chemotherapy in breast cancer—a critical review (2006) (0)
- Early Clinical Studies of (NPAz2)2NSOAz: 'SOAz' (1983) (0)
- Abstract 1751: Systematic bias in genomic breast cancer classification due to selecting cases with high tumor percentage and good RNA quality (2017) (0)
- 10 Homologous recombination deficiency in breast cancer and association with response to neo-adjuvant chemotherapy (2010) (0)
- Chapterr 4. Phasee II study of a multi-course high-dose chemotherapy regimen incorporatingg cyclophosphamide, thiotepa, and carboplatin in stagee IV breast cancer (2007) (0)
- Abstract PD01-04: Histological Features of ER-Low, HER2-Negative Breast Cancer Predict Response to High Dose, Platinum-Based Chemotherapy (2010) (0)
- Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-2004-04) (2017) (0)
- Impact of polymorphisms in the CYP2B6 gene on the pharmacokinetics of cyclophosphamide and thiotepa. (2006) (0)
- Relevance of histological and molecular subtypes in the outcome of primary systemic therapy for operable breast cancer (2008) (0)
- A phase Istudy ofprolonged continuous infusion oflowdoserecombinant interleukin-2 inmelanoma andrenal cellcancer.PartI:clinical aspects (1992) (0)
- Diagnose van tumoren (2002) (0)
- Dutch studies of high-dose chemotherapy with hematopoietic progenitor cell support in high-risk breast cancer (1998) (0)
- Adjuvant therapy for breast cancer (2006) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sjoerd Rodenhuis?
Sjoerd Rodenhuis is affiliated with the following schools: